Cyclopharm Limited Statistics
Want to see AU:CYC full AI Analyst Report?
Cyclopharm Limited (CYC) Stock Statistics & Valuation Metrics
Total Valuation
Cyclopharm Limited has a market cap or net worth of AUD 57.84M. The enterprise value is AUD 51.92M.
- Market Cap
- AUD 57.84M
- Enterprise Value
- AUD 51.92M
Share Statistics
Cyclopharm Limited has 125,734,146 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 125,734,146
- Owned by Insiders
- 4.62%
- Owned by Institutions
- ―
Financial Efficiency
Cyclopharm Limited’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -49.53%.
- Return on Equity (ROE)
- -0.64
- Return on Assets (ROA)
- -0.37
- Return on Invested Capital (ROIC)
- -49.53%
- Return on Capital Employed (ROCE)
- -0.52
- Revenue Per Employee
- 310.82K
- Profits Per Employee
- -165.58K
- Employee Count
- 104
- Asset Turnover
- 0.70
- Inventory Turnover
- 2.95
Valuation Ratios
The current PE Ratio of Cyclopharm Limited is -2.88. Cyclopharm Limited’s PEG ratio is 0.09.
- PE Ratio
- -2.88
- PS Ratio
- 1.68
- PB Ratio
- 1.73
- Price to FCF
- -2.97
- Price to Operating Cash Flow
- -3.15
- PEG Ratio
- 0.09
Income Statement
In the last 12 months, Cyclopharm Limited had revenue of 32.33M and earned -17.22M in profits. Earnings per share was -0.16.
- Revenue
- 32.33M
- Gross Profit
- -1.46M
- Operating Income
- -18.18M
- Pretax Income
- -17.86M
- Net Income
- -17.22M
- EBITDA
- -16.41M
- Earnings Per Share (EPS)
- -0.16
Cash Flow
In the last 12 months, operating cash flow was -17.51M and capital expenditures -1.98M, giving a free cash flow of -19.49M billion.
- Operating Cash Flow
- -17.51M
- Free Cash Flow
- -19.49M
- Free Cash Flow per Share
- -0.16
Dividends & Yields
Cyclopharm Limited pays an annual dividend of AUD 0.01, resulting in a dividend yield of ―
- Dividend Per Share
- AUD 0.01
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -33.70%
- Earnings Yield
- -33.21%
Stock Price Statistics
- Beta
- 0.81
- 52-Week Price Change
- -28.13%
- 50-Day Moving Average
- 0.45
- 200-Day Moving Average
- 0.62
- Relative Strength Index (RSI)
- 54.74
- Average Volume (3m)
- 78.09K
Important Dates
Cyclopharm Limited upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 23, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- Sep 01, 2023
Financial Position
Cyclopharm Limited as a current ratio of 2.53, with Debt / Equity ratio of 55.04%
- Current Ratio
- 2.53
- Quick Ratio
- 1.51
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- -0.51
- Interest Coverage Ratio
- -29.03
Taxes
In the past 12 months, Cyclopharm Limited has paid -636.78K in taxes.
- Income Tax
- -636.78K
- Effective Tax Rate
- 0.04
Enterprise Valuation
Cyclopharm Limited EV to EBITDA ratio is -3.32, with an EV/FCF ratio of -2.74.
- EV to Sales
- 1.55
- EV to EBITDA
- -3.32
- EV to Free Cash Flow
- -2.74
- EV to Operating Cash Flow
- -3.05
Balance Sheet
Cyclopharm Limited has AUD 12.25M in cash and marketable securities with AUD 7.80M in debt, giving a net cash position of AUD 4.44M billion.
- Cash & Marketable Securities
- AUD 12.25M
- Total Debt
- AUD 7.80M
- Net Cash
- AUD 4.44M
- Net Cash Per Share
- AUD 0.04
- Tangible Book Value Per Share
- AUD 0.24
Margins
Gross margin is -1.41%, with operating margin of -51.62%, and net profit margin of -53.23%.
- Gross Margin
- -1.41%
- Operating Margin
- -51.62%
- Pretax Margin
- -54.32%
- Net Profit Margin
- -53.23%
- EBITDA Margin
- -46.77%
- EBIT Margin
- -51.62%
Analyst Forecast
The average price target for Cyclopharm Limited is AUD 1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- AUD 1.00
- Price Target Upside
- 117.39% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 12.05%
- EPS Growth Forecast
- -31.71%
Scores
- Smart Score
- 5
- AI Score
- 47
